- Details
- Joining Alicia Morgans at ASCO GU is Arjun Balar, a bladder cancer expert at New York University, who speaks to the most recent clinical trials and the future direction of available regimens regarding bladder preservation protocols. For the past 30 years, muscle-invasive urothelial cancer patients have been given two options for treatment: radical cystectomy or cisplatinum. With the more recent av...
|
- Details
- Srikala (Kala) Sridhar joins Alicia Morgans to discuss the recent developments in urothelial cancer of the bladder and upper tract. The two discuss controversial issues in urothelial carcinoma from the American Joint Committee on Cancer (AJCC) staging to chemotherapy in upper tract disease, to bladder sparing recent clinical trial findings, and the impact of those trials on clinical practice treat...
|
- Details
- Andrea Necchi, a medical oncologist and Ewan Gibb a researcher at Decipher Biosciences joins Alicia Morgans as they discuss new findings related to bladder cancer and the impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer, an area of unmet need in bladder cancer. The trio cover patient sel...
|
- Details
- Cora Sternberg joins Alicia Morgans at ASCO GU 2020 and discusses the significant advancements in the treatment of advanced bladder cancer looking back over the last 30 years. MVAC was regulatory approved as the first line treatment in metastatic bladder cancer thirty years ago. Cora discusses the recent progress that is offering significant improvements in the overall survival for those patients...
|
- Details
- Alicia Morgans is joined by Peter O’Donnell and Jonathan Rosenberg to discuss enfortumab vedotin (EV). This offers a new mechanism of action and is the first antibody-drug conjugate (ADC). This represents a targeted therapy and was studied in metastatic urothelial carcinoma. In reviewing the clinical data and side effects of the drug, the three clinicians highlight the effectiveness and tolerabili...
|
- Details
- Ashish Kamat sits down with Petros Grivas to discuss the recent advances and clinical trials in second and third-line therapies in metastatic urothelial cancer. Biographies: Petros Grivas, MD, PhD , Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Ashish Kamat, MD,...
|
- Details
- In this conversation, Ronac Mamtani and Ravi Parikh join Alicia Morgans to discuss their recent work on bladder cancer outcomes and effectiveness research. They discuss immune checkpoint therapy versus carboplatin chemotherapy in patients with metastatic urothelial cancer (mUC). They also discuss the "Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cance...
|
- Details
- Bishoy Faltas and Charles Ryan discuss some of Bishoy's work using cell-free DNA, or circulating tumor DNA, and what it means in urothelial cancer today. Circulating tumor DNA is DNA that's shed by the tumor into the bloodstream, and the advantage of the current technology and the evolving technology is that we can actually get that DNA. In this work being discussed Bishoy and colleagues are focus...
|
- Details
- Professor Matt Galsky joins Alicia Morgans to share details of an analysis looking at FGFR mutations in patients who have received checkpoint inhibitor therapy on clinical trials. In this study, Matt Galsky and colleagues examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring C...
|
- Details
- Alicia Morgans and Petros Grivas discuss the use of antibody-drug conjugates (ADC) as a new approach for the treatment of metastatic urothelial carcinoma (mUC). The two review the latest data presented at the 2019 American Society of Clinical Oncology meeting, specifically the use of enfortumab vedotin. Dr. Grivas further discusses sacituzumab govitecan, another popular ADC, and the promising clin...
|
